BCRX - Institutional Ownership: 95%

Sales Growth: +37% (YoY) for the last quarter. The company raised its revenue forecast for Orladeyo to $590 - $600 million for 2025. ✅ OVERCOMING (over 30%).

Gross Margin: For their core product Orladeyo, the margin is over 90%. Overall, for the company, as scale improves, gross profitability remains extremely high. ✅ OVERCOMING.

🏢 Institutional Ownership
This is one of BCRX's strongest points right now:

Institutional Ownership: ~92.5% to 97.7% (according to various sources as of end-2025).

Trend: Big players like Vanguard and BlackRock hold huge positions. The fact that institutions own almost all of the outstanding shares shows that the smart money believes in the long-term potential for $1 billion in sales by 2029.

🚀 Why YES (Buy):
Breakthrough: BioCryst officially reached EPS in the second half of 2025. They are no longer a cash-burning company, but one that generates it.

Huge upside: The average analyst price target is $20.60, which is about a 170% increase from current levels (~$7.50).

Acquisition of Astria: The purchase of Astria Therapeutics (expected to close in Q1 2026) gives them a new drug in the pipeline that could protect them from competition in the future.

⚠️ Risks (Why to be careful):
Single-product dependency: Almost all revenue comes from Orladeyo. If a better alternative emerges, the risk is high.

Competition: New products from giants like Takeda could slow their growth.